Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study
Source: View publication →
In the phase 3 TROPION-Lung01 trial, the TROP2-directed antibody-drug conjugate datopotamab deruxtecan significantly improved progression-free survival with fewer severe treatment-related adverse events compared to docetaxel in previously treated advanced non-small cell lung cancer, with the benefit driven entirely by patients with nonsquamous histology.
Key Findings
Study Design
Study Limitations
Clinical Significance
The TROPION-Lung01 trial establishes datopotamab deruxtecan (Dato-DXd) as a highly active and better-tolerated alternative to docetaxel in previously treated advanced or metastatic nonsquamous NSCLC. By demonstrating a significant progression-free survival benefit and fewer severe treatment-related adverse events, Dato-DXd addresses a major unmet need in the second-line setting, where docetaxel has historically provided marginal benefit with substantial toxicity. Furthermore, the stark divergence in outcomes between squamous and nonsquamous histologies underscores the importance of histology-directed application of this TROP2-directed ADC. Data from this trial and TROPION-Lung05 supported the FDA accelerated approval of Dato-DXd for pretreated EGFR-mutated NSCLC.
Historical Context
For more than two decades, docetaxel has remained the standard of care for patients with advanced NSCLC who progress on platinum-based chemotherapy and immunotherapy, despite its limited efficacy and significant toxicities such as myelosuppression and neuropathy. With the advent of antibody-drug conjugates (ADCs), targeting widely expressed surface antigens like TROP2 has emerged as a promising strategy. Following the success of ADCs such as sacituzumab govitecan and trastuzumab deruxtecan in other solid tumors, Dato-DXd was developed utilizing a potent topoisomerase I inhibitor payload. TROPION-Lung01 is the first phase 3 trial to successfully demonstrate that a TROP2-directed ADC can outperform standard docetaxel in pretreated nonsquamous NSCLC, marking a major milestone in transitioning away from traditional chemotherapy.
Guided Discussion
High-yield insights from every perspective
What is the mechanism of action of datopotamab deruxtecan as an antibody-drug conjugate, and what basic pathophysiological differences might explain why its efficacy in this trial was driven entirely by patients with nonsquamous rather than squamous non-small cell lung cancer?
Key Response
Datopotamab deruxtecan consists of a monoclonal antibody targeting TROP2 linked to a topoisomerase I inhibitor. Understanding the selective delivery of cytotoxic payloads via ADCs is a foundational pharmacological concept. The histological divergence in efficacy prompts students to explore how TROP2 expression levels, tumor microenvironment, or structural cellular differences between squamous and nonsquamous carcinomas affect drug internalization and action.
In the second-line setting for advanced NSCLC, docetaxel has historically been the standard of care. Based on the TROPION-Lung01 results, how does the toxicity profile of datopotamab deruxtecan compare to docetaxel, and how would this shift influence your clinical management and monitoring of a patient with previously treated nonsquamous NSCLC?
Key Response
Docetaxel is notorious for severe myelosuppression, neuropathy, and alopecia. The trial showed datopotamab deruxtecan had fewer severe (Grade 3 or higher) treatment-related adverse events, but introduced different toxicities like stomatitis and interstitial lung disease (ILD). Residents must know how to translate these differing toxicity profiles into practical management decisions and tailored patient monitoring protocols.
Given that the progression-free survival benefit of datopotamab deruxtecan was isolated to the nonsquamous subgroup, how should this influence our approach to biomarker testing for TROP2-directed therapies, and should TROP2 immunohistochemistry or genomic profiling become a prerequisite for patient selection?
Key Response
Fellows must navigate the complex landscape of precision oncology. Currently, TROP2-directed ADCs are often developed without requiring a companion diagnostic for TROP2 expression. This question forces fellows to critically evaluate whether histology alone is a sufficient clinical biomarker, or if the field needs more nuanced molecular or genomic profiling to identify true responders and avoid ineffective therapy in squamous patients.
While datopotamab deruxtecan demonstrates a statistically significant progression-free survival benefit in nonsquamous NSCLC, mature overall survival data is still pending. How do you weigh this PFS benefit against the unique ADC-related toxicities, such as interstitial lung disease, when counseling a patient in the second-line setting to ensure the intervention is clinically meaningful?
Key Response
Attendings must balance statistical significance with real-world clinical utility and quality of life. Replacing docetaxel with an ADC introduces potentially fatal toxicities like ILD. Evaluating the tradeoff between a progression-free survival advantage (often measured in months) and the risk of novel toxicities highlights the advanced art of shared decision-making in palliative oncology.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The TROPION-Lung01 trial was an open-label study where a profound efficacy difference between squamous and nonsquamous histology emerged. Methodologically, how does the initial stratification, powering, and alpha-spending plan of the trial impact the statistical validity of concluding that the drug is ineffective in the squamous subgroup?
Key Response
PhD researchers focus heavily on trial design and statistical robustness. If a study was not initially powered or strictly stratified to detect non-inferiority or lack of efficacy in specific histological subgroups, post-hoc or secondary subgroup analyses run the risk of Type II errors or being confounded by baseline imbalances, making the methodological critique of these claims essential.
As a peer reviewer evaluating the TROPION-Lung01 manuscript, how significant a threat to internal validity is the open-label design regarding the primary endpoint of progression-free survival, particularly considering that the distinct adverse event profiles of the ADC and docetaxel effectively unblind both the investigator and the patient?
Key Response
Journal editors and reviewers must identify subtle biases. Even with blinded independent central review (BICR), functional unblinding due to distinct toxicities (e.g., stomatitis for the ADC vs. severe neutropenia for docetaxel) can bias investigator behavior, such as the timing of off-schedule scans or clinical progression declarations, potentially skewing PFS results.
Current guidelines, such as NCCN and ASCO, recommend docetaxel with or without ramucirumab for second-line NSCLC without actionable mutations. Based on the TROPION-Lung01 data, should datopotamab deruxtecan replace docetaxel as a Category 1 recommendation specifically for nonsquamous NSCLC, and is the evidence strong enough to issue a formal recommendation against its use in squamous histology?
Key Response
Guideline committees must decide if new phase 3 data is robust enough to alter established algorithms. They need to determine the strength of recommendation and level of evidence for establishing a histology-specific pathway in the second line, and decide if the lack of benefit in the squamous subgroup warrants an exclusionary guideline, which would significantly alter clinical pathways.
Clinical Landscape
Noteworthy Related Trials
REVEL Trial
Tested
Ramucirumab plus docetaxel
Population
Patients with stage IV NSCLC progressing after platinum-based therapy
Comparator
Placebo plus docetaxel
Endpoint
Overall survival (OS)
CheckMate 057 Trial
Tested
Nivolumab 3 mg/kg IV every 2 weeks
Population
Patients with previously treated advanced non-squamous NSCLC
Comparator
Docetaxel 75 mg/m2 IV every 3 weeks
Endpoint
Overall survival (OS)
OAK Trial
Tested
Atezolizumab 1200 mg IV every 3 weeks
Population
Patients with previously treated advanced NSCLC
Comparator
Docetaxel 75 mg/m2 IV every 3 weeks
Endpoint
Overall survival (OS)
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis